#ariba_ref_name	ref_name	gene	var_only	flag	reads	cluster	ref_len	ref_base_assembled	pc_ident	ctg	ctg_len	ctg_cov	known_var	var_type	var_seq_type	known_var_change	has_known_var	ref_ctg_change	ref_ctg_effect	ref_start	ref_end	ref_nt	ctg_start	ctg_end	ctg_nt	smtls_total_depth	smtls_nts	smtls_nts_depth	var_description	free_text
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15042	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2322	789.6	0	.	n	.	0	C1450T	SNP	1450	1450	C	1820	1820	T	979	T,C,G,A	975,2,1,1	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15042	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2322	789.6	1	SNP	n	C1184T	0	.	.	1184	1184	C	1554	1554	C	971	C	971	16S.rDNA_WHO_F_01361c:0:1:C1184T:16S.1184T:E coli C1192T. Resistance to Spectinomycin	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15042	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2322	789.6	0	HET	.	.	.	A69G	.	69	69	A	439	439	A	981	A,G	760,217	.	.
16S.rDNA_WHO_F_01361c	16S.rDNA_WHO_F_01361c	0	1	659	15042	16S	1529	1529	99.93	16S.l6.c30.ctg.1	2322	789.6	0	HET	.	.	.	C262T,A	.	262	262	C	632	632	C	848	C,T,A	674,173,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25566	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4056	785.9	0	.	n	.	0	G1337A	SNP	1337	1337	G	1955	1955	A	1066	A,G,C	1063,2,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25566	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4056	785.9	0	.	n	.	0	T1971C	SNP	1971	1971	T	2589	2589	C	856	C,T,A	854,1,1	.	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25566	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4056	785.9	1	SNP	n	A2045G	0	.	.	2045	2045	A	2663	2663	A	766	A,C,T	763,2,1	23S.rDNA_WHO_F_01358c:0:1:A2045G:23S.2045G:E coli A2059G. High-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25566	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4056	785.9	1	SNP	n	C2597T	0	.	.	2597	2597	C	3215	3215	C	964	C,T	963,1	23S.rDNA_WHO_F_01358c:0:1:C2597T:23S.2597T :E coli C2611T. Low-level resistance to Azithromycin	.
23S.rDNA_WHO_F_01358c	23S.rDNA_WHO_F_01358c	0	1	659	25566	23S	2890	2890	99.93	23S.l15.c4.ctg.1	4056	785.9	0	HET	.	.	.	G851GA,GAA	.	851	851	G	1469	1469	G	1007	GA,GAA	726,243	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2286	folP	852	852	99.88	folP.l15.c17.ctg.1	1816	155.9	0	.	p	.	0	E151K	NONSYN	451	453	GAA	914	916	AAA	241;241;239	A,G,C;A;A,C	239,1,1;241;238,1	.	.
folP.WHO_K_01359c	folP.WHO_K_01359c	1	1	539	2286	folP	852	852	99.88	folP.l15.c17.ctg.1	1816	155.9	1	SNP	p	R228S	1	.	.	682	684	AGC	1145	1147	AGC	206;205;208	A,T;G;C	205,1;205;208	folP.WHO_K_01359c:1:1:R228S:folP.228S:Resistance to sulphonamides	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5656	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3717	189.2	1	SNP	p	S91F	0	.	.	271	273	TCC	707	709	TCC	222;223;223	T,G;C;C,A	221,1;223;222,1	gyrA.WHO_F_00668c:1:1:S91F:gyrA.91F:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5656	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3717	189.2	1	SNP	p	D95G	0	.	.	283	285	GAC	719	721	GAC	241;239;238	G;A,T;C	241;238,1;238	gyrA.WHO_F_00668c:1:1:D95G:gyrA.95G:Resistance to fluoroquinolones	.
gyrA.WHO_F_00668c	gyrA.WHO_F_00668c	1	1	27	5656	gyrA	2751	2751	100.0	gyrA.l15.c4.ctg.1	3717	189.2	1	SNP	p	D95N	0	.	.	283	285	GAC	719	721	GAC	241;239;238	G;A,T;C	241;238,1;238	gyrA.WHO_F_00668c:1:1:D95N:gyrA.95N:Resistance to fluoroquinolones	.
mtrR.WHO_V_01454	mtrR.WHO_V_01454	1	1	27	2004	mtrR	633	633	100.0	mtrR.l15.c30.ctg.1	1721	145.1	1	SNP	p	G45D	0	.	.	133	135	GGC	686	688	GGC	218;217;216	GGCGCGC,GGCGC;G;C	206,1;217;216	mtrR.WHO_V_01454:1:1:G45D:mtrR.45D:Increased efflux of antimicrobials, e.g. macrolides and b-lactam antimicrobials, that are substrates of the MtrCDE efflux pump	.
mtrR_promoter.WHO_F	mtrR_promoter.WHO_F	0	0	531	1190	mtrR_promoter	250	250	99.6	mtrR_promoter.l15.c4.ctg.1	1447	102.6	0	.	n	.	0	A197.	DEL	197	197	A	823	823	A	231	A	231	.	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5092	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3457	183.7	1	SNP	p	D86N	0	.	.	256	258	GAC	810	812	GAC	246;245;245	G;A,C;C,A	246;244,1;244,1	parC.WHO_M_00204c:1:1:D86N:parC.86N:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5092	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3457	183.7	1	SNP	p	S87R	0	.	.	259	261	AGT	813	815	AGT	248;252;253	A;G;T	248;252;253	parC.WHO_M_00204c:1:1:S87R:parC.87R:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5092	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3457	183.7	1	SNP	p	S87W	0	.	.	259	261	AGT	813	815	AGT	248;252;253	A;G;T	248;252;253	parC.WHO_M_00204c:1:1:S87W:parC.87W:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5092	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3457	183.7	1	SNP	p	S87I	0	.	.	259	261	AGT	813	815	AGT	248;252;253	A;G;T	248;252;253	parC.WHO_M_00204c:1:1:S87I:parC.87I:Resistance to fluoroquinolones	.
parC.WHO_M_00204c	parC.WHO_M_00204c	1	1	27	5092	parC	2304	2304	99.91	parC.l15.c4.ctg.1	3457	183.7	1	SNP	p	S88P	0	.	.	262	264	TCC	816	818	TCC	254;255;257	T,G;C;C	253,1;255;257	parC.WHO_M_00204c:1:1:S88P:parC.88P:Resistance to fluoroquinolones	.
parE.WHO_F_01528c	parE.WHO_F_01528c	1	1	27	4376	parE	1986	1986	100.0	parE.l15.c4.ctg.1	3289	166.0	1	SNP	p	G410V	0	.	.	1228	1230	GGC	1901	1903	GGC	237;236;234	G,A,T;G;C,T	234,2,1;236;232,2	parE.WHO_F_01528c:1:1:G410V:parE.410V:Resistance to fluoroquinolones	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	A311V	0	.	.	931	933	GCA	1478	1480	GCA	272;273;273	G,T;C;A	271,1;273;273	penA.9.001:1:1:A311V:penA.311V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	I312M	0	.	.	934	936	ATC	1481	1483	ATC	272;273;272	A;T;C,A	272;273;270,2	penA.9.001:1:1:I312M:penA.312M:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	V316P	0	.	.	946	948	GTG	1493	1495	GTG	265;268;268	G,A;T,G;G	264,1;267,1;268	penA.9.001:1:1:V316P:penA.316P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	V316T	0	.	.	946	948	GTG	1493	1495	GTG	265;268;268	G,A;T,G;G	264,1;267,1;268	penA.9.001:1:1:V316T:penA.316T:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	T484S	0	.	.	1450	1452	ACC	1997	1999	ACC	203;205;205	A;C,G,A;C	203;203,1,1;205	penA.9.001:1:1:T484S:penA.483S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	A502V	0	.	.	1504	1506	GCG	2051	2053	GCG	204;205;205	G;C,T;G	204;204,1;205	penA.9.001:1:1:A502V:penA.501V:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	A502P	0	.	.	1504	1506	GCG	2051	2053	GCG	204;205;205	G;C,T;G	204;204,1;205	penA.9.001:1:1:A502P:penA.501P:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	G543S	0	.	.	1627	1629	GGC	2174	2176	GGC	221;222;223	G,T;G,T;C	220,1;221,1;223	penA.9.001:1:1:G543S:penA.542S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	G546S	0	.	.	1636	1638	GGC	2183	2185	GGC	225;225;225	G;G;C	225;225;225	penA.9.001:1:1:G546S:penA.545S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
penA.9.001	penA.9.001	1	1	27	4242	penA	1749	1749	100.0	penA.l15.c4.ctg.1	2832	186.7	1	SNP	p	L552S	0	.	.	1654	1656	CTG	2201	2203	CTG	235;237;238	C;T;G,T	235;237;237,1	penA.9.001:1:1:L552S:penA.551S:Resistance to Extended-Spectrum Cephalosporins (ESCs)	.
ponA.WHO_G_00106	ponA.WHO_G_00106	1	1	27	5878	ponA	2397	2397	100.0	ponA.l15.c4.ctg.1	3531	207.3	1	SNP	p	L421P	1	.	.	1261	1263	CCG	1834	1836	CCG	258;259;258	C;C,T;G,T	258;258,1;257,1	ponA.WHO_G_00106:1:1:L421P:ponA.421P:High-level chromosomally-mediated penicillin resistance	.
porA.NCCP11945	porA.NCCP11945	1	0	531	2310	porA	1146	1146	99.65	porA.l6.c17.ctg.1	2290	125.8	0	.	p	.	0	M83fs	FSHIFT	247	247	A	797	797	C	180	C	180	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	V258L	NONSYN	772	774	GTA	14	16	TTA	30;30;32	T,G;T;A	29,1;30;32	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	Y273H	NONSYN	817	819	TAT	59	61	CAT	58;58;58	C;A;T	58;58;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	D274S	NONSYN	820	822	GAT	62	64	AGT	58;58;58	A;G;T	58;58;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	N277Y	NONSYN	829	831	AAC	71	73	TAC	58;58;58	T;A;C	58;58;58	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	R307A	NONSYN	919	921	AGA	161	163	GCA	1;1;1	G;C;A	1;1;1	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	T311A	NONSYN	931	933	ACA	173	175	GCA	2;2;2	G;C;A	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	E312D	NONSYN	934	936	GAA	176	178	GAC	2;2;2	G;A;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	F314I	NONSYN	940	942	TTC	182	184	ATC	2;2;2	A;T;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	A316S	NONSYN	946	948	GCG	188	190	TCG	2;2;2	T;C;G	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	V318A	NONSYN	952	954	GTC	194	196	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	G319S	NONSYN	955	957	GGC	197	199	AGC	2;2;2	A;G;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	G320A	NONSYN	958	960	GGT	200	202	GCC	2;2;2	G;C;C	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	226	90.27	porB1a.l15.c17.ctg.2	556	20.2	0	.	p	.	0	G322V	NONSYN	964	966	GGT	206	208	GTT	2;2;2	G;T;T	2;2;2	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	100	95.0	porB1a.l15.c17.ctg.3	182	43.9	0	.	p	.	0	M18T	NONSYN	52	54	ATG	133	135	ACG	54;53;50	A;C;G	54;53;50	.	.
porB1a.WHO_F_02106	porB1a.WHO_F_02106	1	0	512	266	porB1a	984	100	95.0	porB1a.l15.c17.ctg.3	182	43.9	0	.	p	.	0	E32Q	NONSYN	94	96	GAA	175	177	CAA	15;15;12	C;A;A	15;15;12	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	0	.	p	.	0	N38E	NONSYN	112	114	AAT	583	585	GAA	266;268;270	G,A;A,C;A,C	265,1;267,1;269,1	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	0	.	p	.	0	N134D	NONSYN	400	402	AAT	871	873	GAT	241;239;238	G,A;A,C;T	240,1;237,2;238	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	0	.	p	.	0	P175S	NONSYN	523	525	CCA	994	996	TCA	243;241;241	T,C;C;A	242,1;241;241	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	0	.	p	.	0	A218V	NONSYN	652	654	GCC	1123	1125	GTC	290;289;287	G,T;T;C	289,1;289;287	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	0	.	p	.	0	E328A	NONSYN	982	984	GAA	1453	1455	GCA	260;259;263	G;C;A	260;259;263	.	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	1	SNP	p	G120K	1	.	.	358	360	AAG	829	831	AAG	235;237;235	A,G;A,C;G,T	234,1;236,1;233,2	porB1b.WHO_V_02265c:1:1:G120K:porB1b.120K:G101K. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	1	SNP	p	D121N	0	.	.	361	363	GAC	832	834	GAC	234;234;235	G;A;C	234;234;235	porB1b.WHO_V_02265c:1:1:D121N:porB1b.121N:A102N. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
porB1b.WHO_V_02265c	porB1b.WHO_V_02265c	1	1	539	2988	porB1b	1047	1047	99.33	porB1b.l15.c30.ctg.1	1859	198.7	1	SNP	p	A121D	1	.	.	361	363	GAC	832	834	GAC	234;234;235	G;A;C	234;234;235	porB1b.WHO_V_02265c:1:1:A121D:porB1b.121D:A102D. Mediates decreased permeability of antimicrobials through the porin PorB1b	.
rpoB.WHO_F_02153c	rpoB.WHO_F_02153c	1	1	539	10066	rpoB	4179	4179	99.98	rpoB.l15.c4.ctg.1	5416	231.8	1	SNP	p	H553N	1	H553N	NONSYN	1657	1659	CAT	2243	2245	AAT	282;283;285	A;A;T	282;283;285	rpoB.WHO_F_02153c:1:1:H553N:rpoB.553N:H552N. High-level resistance to Rifampicin	.
rpsJ.WHO_Y_02241	rpsJ.WHO_Y_02241	1	1	27	1496	rpsJ	312	312	100.0	rpsJ.l6.c17.ctg.1	1323	140.0	1	SNP	p	V57M	1	.	.	169	171	ATG	662	664	ATG	269;271;269	A;T;G	269;271;269	rpsJ.WHO_Y_02241:1:1:V57M:rpsJ.57M:Chromosomally-mediated resistance to tetracyclines	.
